Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678702 | 0.81 | CA2 (0.50) | CA1CA2NAMPTPTGER4KDM5B | |
| SCHEMBL1936202 | 0.75 | MGLL (0.55) | ALDH1A1CA1CA2NAMPTMAPT | |
| SCHEMBL6541375 | 0.74 | KMT2A (0.46) | ALDH1A1LMNAHTT | |
| SCHEMBL27741035 | 0.73 | CA2 (0.56) | CA1CA2NAMPTMAPTTDP1 | |
| SCHEMBL23291128 | 0.73 | CYP17A1 (0.59) | CA1CA2NAMPTMAPTTDP1 | |
| SCHEMBL7091943 | 0.72 | CA2 (0.48) | ALDH1A1CA1CA2NAMPTMAPT | |
| SCHEMBL2024124 | 0.72 | CYP17A1 (0.53) | ALDH1A1CA1CA2NAMPTMAPT | |
| SCHEMBL19939942 | 0.72 | NPSR1 (0.44) | ALDH1A1CA1CA2NAMPTMAPT | |
| SCHEMBL4465651 | 0.72 | MGLL (0.51) | CA1CA2NAMPTMAPTPTGER4 | |
| SCHEMBL6539884 | 0.71 | MAPT (0.43) | ALDH1A1CA1CA2NAMPTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | ALDH1A1 168/4885CA1 2450/4885CA2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.